EUVIMEDOpdag EUVIMED
VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Comparative long‐term efficacy and safety of two paclitaxel‐coated balloons with different coating strategies for the treatment of drug‐eluting coronary stent restenosis

Tobias Koch iD, Tobias Lenz, Tobias Rheude, Salvatore Cassese, Erion Xhepa, Michael Joner, Julinda Mehilli, Heribert Schunkert, Adnan Kastrati iD, Sebastian Kufner

Catheterization and Cardiovascular Interventions · 2024-11 · 104 (5) · 909-917

DOI: 10.1002/ccd.31228 ↗

At a glance

Vergleichsstudie in Catheterization and Cardiovascular Interventions, published online on 2024-09-18. Written by Tobias Koch and 9 co-authors. Institution: ISAResearch Zentrum, Kardiologie, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. Major MEDLINE topics: Angioplasty, Balloon, Coronary, Cardiac Catheters, Coated Materials, Biocompatible, Coronary Restenosis. Cited 4 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Boston Scientific.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

We previously showed non‐inferiority of a low‐dose paclitaxel‐coated balloon (PCB) with citrate excipient (Agent PCB) as compared to normal‐dose iopromide excipient (SeQuent Please PCB) in terms of angiographic and clinical endpoints at 12 months. The long‐term clinical efficacy and safety of Agent PCB is not defined.

Methods

262 patients (323 DES‐ISR lesions) were enrolled in this study and treated with either Agent PCB (125 patients, 151 lesions) in the ISAR‐DESIRE 3a trial or with SeQuent Please PCB (137 patients, 172 lesions) in the setting of the randomized ISAR‐DESIRE 3 trial with similar in‐ and exclusion criteria serving as historical control arm. The follow‐up period was extended to 7 years. The efficacy and safety endpoints of this analysis were target‐lesion revascularization (TLR), death, myocardial infarction (MI) and target lesion thrombosis (TLT) at 7 years.

Results

At 7 years, 206 patients (78.6%) were alive. The risks of TLR (hazard ratio [HR]: 1.29, 95% confidence interval [CI]: 0.87–1.90; p = 0.205), death (HR: 1.38, 95% CI: 0.82‐2.35; p = 0.227), MI (HR: 1.10, 95% CI: 0.39–3.15; p = 0.852) and TLT (HR: 2.18, 95% CI: 0.20–24.10; p = 0.523) were comparable between Agent PCB and SeQuent PCB. Multivariate analysis showed comparable risks of TLR, death and MI between both PCB devices.

Conclusions

In patients treated for DES‐ISR by angioplasty with Agent PCB and SeQuent Please PCB, there was no statistically significant difference in TLR at 7 years. Randomized trials with standardized lesion preparation and long‐term follow‐up are warranted to further evaluate comparative efficacy of both devices. (ClinicalTrials. gov Identifier: NCT02367495).

Subjects

MeSH terms (MEDLINE)

Angioplasty, Balloon, CoronaryCardiac CathetersCoated Materials, BiocompatibleCoronary RestenosisDrug-Eluting StentsPaclitaxelAgedFemaleHumansMaleMiddle AgedCardiovascular AgentsCitric AcidCoronary Artery DiseaseCoronary ThrombosisIohexolMyocardial InfarctionProspective StudiesRisk FactorsTime FactorsTreatment Outcome

Author keywords

drug‐coated balloon (DCB)drug‐eluting‐stent (DES)in‐stent restenosis (ISR)paclitaxel

Substances

Cardiovascular AgentsCitric AcidCoated Materials, BiocompatibleIohexoliopromidePaclitaxel

Authors and institutions

  • ISAResearch Zentrum, Kardiologie, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
  • Deutsches Zentrum für Herz-Kreislauf-Forschung, Partner Site Munich Heart Alliance, Munich, Germany.
  • Medizinische Klinik I, Krankenhaus Landshut-Achdorf, Landshut, Germany.

ORCID profiles: Tobias Koch, Adnan Kastrati

Funding

  • Boston Scientific

Cite

APA

Koch, T., Lenz, T., Rheude, T., Cassese, S., Xhepa, E., Joner, M., Mehilli, J., Schunkert, H., Kastrati, A., & Kufner, S. (2024). Comparative long‐term efficacy and safety of two paclitaxel‐coated balloons with different coating strategies for the treatment of drug‐eluting coronary stent restenosis. Catheterization and Cardiovascular Interventions, 104(5), 909-917. https://doi.org/10.1002/ccd.31228

Vancouver

Koch T, Lenz T, Rheude T, Cassese S, Xhepa E, Joner M, et al. Comparative long‐term efficacy and safety of two paclitaxel‐coated balloons with different coating strategies for the treatment of drug‐eluting coronary stent restenosis. Catheterization and Cardiovascular Interventions. 2024;104(5):909-917. doi:10.1002/ccd.31228

BibTeX
@article{Koch2024,
  author = {Koch, Tobias and Lenz, Tobias and Rheude, Tobias and Cassese, Salvatore and Xhepa, Erion and Joner, Michael and Mehilli, Julinda and Schunkert, Heribert and Kastrati, Adnan and Kufner, Sebastian},
  title = {Comparative long‐term efficacy and safety of two paclitaxel‐coated balloons with different coating strategies for the treatment of drug‐eluting coronary stent restenosis},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2024},
  volume = {104},
  number = {5},
  pages = {909--917},
  doi = {10.1002/ccd.31228}
}
Start for free →